PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of wtpaEurope PMCEurope PMC Funders GroupSubmit a Manuscript
 
Nature. Author manuscript; available in PMC May 1, 2011.
Published in final edited form as:
PMCID: PMC2975378
UKMSID: UKMS31960
Antibodies to human serum amyloid P component eliminate visceral amyloid deposits
Karl Bodin,1* Stephan Ellmerich,1* Melvyn C. Kahan,1 Glenys A. Tennent,1 Andrzej Loesch,1 Janet A. Gilbertson,1 Winston L. Hutchinson,1 Palma P. Mangione,1,2 J. Ruth Gallimore,1 David J. Millar,1 Shane Minogue,3 Amar P. Dhillon,4 Graham W. Taylor,1 Arthur R. Bradwell,5 Aviva Petrie,6 Julian D. Gillmore,1 Vittorio Bellotti,1,2 Marina Botto,7 Philip N. Hawkins,1 and Mark B. Pepys1
1Centre for Amyloidosis and Acute Phase Proteins, Division of Medicine, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK
2Dipartimento di Biochimica, Università di Pavia, Via Taramelli 3b, 27100 Pavia, Italy
3Centre for Molecular Cell Biology, Division of Medicine, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK
4Department of Histopathology, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK
5Department of Immunity and Infection, The Medical School, University of Birmingham, Birmingham B15 2TT, UK & The Binding Site Ltd, Birmingham, B14 4ZB, UK
6Biostatistics Unit, UCL Eastman Dental Institute, 256 Grays Inn Road, London WC1X 8LD, UK
7Rheumatology Section, Faculty of Medicine, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0NN, UK
Correspondence and request for materials should be addressed to M.B.P. (m.pepys/at/ucl.ac.uk).
*These authors contributed equally to this work.
Author contributions The study was conceived, designed and supervised by M.B.P. K.B., M.C.K. and S.E. performed all the experimental animal work. G.A.T., A.L., J.A.G., S.M. and A.P.D. performed or contributed to the histological studies. Amyloid scoring was performed by K.B., M.C.K., S.E., J.D.G. and M.B.P. W.L.H., P.P.M., J.R.G., D.J.M., G.W.T. and V.B. conducted the immunochemical, radiochemical and immunoassay studies. A.P. undertook the statistical analyses. A.R.B. produced the sheep anti-human SAP and control antisera. M.B. supplied the complement knockout mice. J.D.G. and P.N.H. contributed to experimental design. The paper was written by M.B.P. and reviewed and approved by all co-authors.
Author information Reprints and permissions information is available at www.nature.com/reprints. M.B.P. is the inventor on patents covering SAP as a therapeutic target in amyloidosis and amyloid-associated diseases, and the use of CPHPC for SAP depletion, owned by Pentraxin Therapeutics Ltd, a University College London spinout company in which he and P.N.H. own shares. Pentraxin Therapeutics Ltd owns the patents on CPHPC itself and has licensed the intellectual property relevant to the present work to GlaxoSmithKline.
Accumulation of amyloid fibrils in the viscera and connective tissues causes systemic amyloidosis, which is responsible for about one per thousand deaths in developed countries1. Localised amyloid can also be very serious, for example cerebral amyloid angiopathy is an important cause of haemorrhagic stroke. The clinical presentations of amyloidosis are extremely diverse and the diagnosis is rarely made before significant organ damage is present1. There is therefore a major unmet medical need for therapy which safely promotes the clearance of established amyloid deposits. Over 20 different amyloid fibril proteins are responsible for different forms of clinically significant amyloidosis and treatments that substantially reduce the abundance of the respective amyloid fibril precursor protein can arrest amyloid accumulation1. Unfortunately control of fibril protein production is not possible in some forms of amyloidosis and in others is often slow and hazardous1. There is no therapy that directly targets amyloid deposits for enhanced clearance. However, all amyloid deposits contain the normal, non-fibrillar, plasma glycoprotein, serum amyloid P component (SAP)2, 3. Here we show that administration of anti-human SAP antibodies to mice with amyloid deposits containing human SAP, triggers a potent, complement dependent, macrophage-derived giant cell reaction which swiftly removes massive visceral amyloid deposits without adverse effects. Anti-SAP antibody treatment is clinically feasible because circulating human SAP can be depleted in patients by the bis-D-proline compound, CPHPC4, thereby enabling injected anti-SAP antibodies to reach residual SAP in the amyloid deposits. The unprecedented capacity of this novel combined therapy to eliminate amyloid deposits should be applicable to all forms of systemic and local amyloidosis.
Serum amyloid P component (SAP) is selectively concentrated in amyloid deposits by its avid binding to all amyloid fibril types2,3. SAP binding stabilises amyloid fibrils, protects them from proteolysis in vitro5 and contributes to pathogenesis of systemic amyloidosis in vivo6. We therefore developed a novel bis-D-proline compound, (R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid, (CPHPC), which is bound with high affinity by human SAP and triggers its rapid clearance by the liver, thereby depleting circulating SAP by more than 90% for as long as the drug is administered4,7. However, some SAP remains bound to amyloid even after months of CPHPC treatment7. Here we have targeted this residual SAP with IgG antibodies, triggering the body’s potent phagocytic clearance mechanisms (Supplementary 1).
Splenic and hepatic AA amyloid deposition, closely resembling human systemic AA amyloidosis, was induced by chronic inflammation in C57BL/6 mice deficient in mouse SAP but transgenic for human SAP4. Human SAP is present in their circulation, in normal extracellular matrix8,9 (Supplementary 2), and in the amyloid deposits (Supplementary 3), just as in humans. Amyloid was quantified in each mouse by whole body retention of 125I-SAP (ref. 10) and the mice were allocated to three groups closely matched for age, sex and amyloid load. The model closely reflects clinical amyloidosis because human SAP binds much more avidly to amyloid than does mouse SAP10, and CPHPC depletes circulating human but not mouse SAP in vivo4. Two groups of mice then received CPHPC at 1 mg/ml in their drinking water for the rest of the experiment. Circulating human SAP was depleted but, as in humans treated with CPHPC, significant amounts of SAP remained in the amyloid deposits (Supplementary 4). Five days after starting on CPHPC, one group received a single intraperitoneal injection of 50 mg of the IgG fraction of monospecific polyclonal sheep anti-human SAP antiserum, containing 7 mg of anti-SAP antibody. A control group received 50 mg of unrelated sheep IgG (Supplementary 4). The third group received no treatment and thus controlled for spontaneous regression of AA amyloid11. Twenty eight days after the antibody or control IgG injection, the visceral amyloid load was scored histologically and human SAP was quantified in the individual sera and organs (Supplementary 4).
There was dramatically less amyloid after treatment with CPHPC plus anti-SAP antibody than in the other two groups but there was no difference between CPHPC alone and no treatment (Fig. 1, Supplementary 4). Apart from the amyloid deposits there were no other significant histological abnormalities in any animal. Anti-SAP antibody thus produced remarkable regression of amyloid with no disruption to the normal parenchymal or connective tissue structure of the liver, spleen or other organs. Furthermore there were no clinical or biochemical adverse effects, no mice died during the experiment and body weights remained constant (Supplementary 5).
Figure 1
Figure 1
Elimination of visceral amyloid in AA amyloidotic mice after treatment with anti-SAP antibody
Systemic amyloid deposits are characteristically acellular with no surrounding inflammatory reaction (Figs. 2l, 2p, ,3a).3a). However by 24 h after injection of anti-SAP antibody all the deposits were densely infiltrated with mononuclear inflammatory cells and some granulocytes (Figs. 2b, 2m, 2q). Most infiltrating cells stained strongly with antibody to F4/80, a global macrophage marker (Fig. 2b). No such staining was present in amyloid deposits in mice not receiving anti-SAP. On day 2 macrophages surrounding the amyloid were fusing to form multinucleate giant cells and stained strongly for CD68, a marker of phagocyte endocytotic activity, which co-localised with staining for the amyloid fibril AA protein and mouse complement component C3 (Figs. 2e-2k, 3b, 3c, Supplementary 6). By day 4 the deposits were less abundant and were fragmented by numerous multinucleate giant cells surrounding and engulfing islands of amyloid (Figs. 2c, 2d, 2e, 2n, 2r). At day 7 residual amyloid was mostly being degraded within the cytoplasm of decreasing numbers of giant cells. Amyloid clearance was largely complete by about day 16 with remarkable restoration of normal tissue architecture and absence of any residual cellular infiltrate (Figs. 2o, 2s).
Figure 2
Figure 2
Cellular infiltration and amyloid destruction after administration of anti-SAP antibody
Figure 3
Figure 3
Electron micrographs of amyloid destruction after anti-SAP antibody treatment
Human SAP binds avidly to mouse AA deposits in vivo and persists there with a half life of 3-4 days, while circulating human SAP is cleared in mice with a half life of 3-4 hours and is undetectable in the plasma after 3 days4,10. Amyloid deposits in non-transgenic AA amyloidotic C57BL/6 mice were thus loaded with human SAP by a single intraperitoneal injection of 10 mg of the isolated pure protein and anti-human SAP antibody was injected 3 days later without the need for CPHPC. The same highly reproducible amyloid elimination occurred as in the human SAP transgenic mice and this approach facilitated analysis of the mechanisms responsible.
In contrast to the clearance of amyloid deposits in wild type mice, significantly more amyloid remained after anti-SAP treatment of complement deficient animals lacking either C1q12 or C313 (Supplementary 7), demonstrating that the antibody effect is largely complement dependent. IgG antibody alone could potentially engage phagocytic cells via their Fc(γ) receptors and, although amyloid clearance was much reduced in the absence of complement, the persistent deposits in complement deficient mice were more fragmented than in untreated controls, suggesting some direct antibody effect. There was more complete amyloid elimination in some C1q deficient mice than in C3 deficient animals (Supplementary 7) suggesting that complement activation may occur in the absence of C1q but that C3 is critical. Consistent with this observation, F(ab)2 anti-SAP antibody treatment reduced amyloid load but was significantly less effective than intact IgG antibody (Supplementary 8). F(ab)2 antibodies activate the alternative pathway, independently of C1q, and it is likely that the high dose of F(ab)2 which was used (Supplementary 8) triggered some complement activation. Full efficacy of anti-SAP antibody thus requires the Fc region but cellular recognition by Fc(γ) receptors is not a major factor since F(ab)2 was more effective in complement sufficient mice than IgG antibody in complement deficient animals.
When macrophage activity was ablated using liposomal clodronate14, anti-SAP antibody produced no reduction of amyloid load (Supplementary 9), demonstrating that macrophages were the essential final effectors of amyloid clearance. Macrophages are largely responsible for the normal, clinically silent, resolution of non-infective tissue injury and for remodelling of non-cellular matrix. The failure to spontaneously clear amyloid deposits, which are composed only of autologous constituents, is therefore remarkable especially as, despite their inherent stability, amyloid fibrils can be digested by proteinases and phagocytic cells in vitro5, especially when opsonised by antibody15. In vivo macrophage responses to different types of amyloid have been reported occasionally16-19, and amyloid deposits sometimes regress when fibril precursor protein abundance is sufficiently reduced20, 21. However amyloid usually accumulates with little or no local cellular or systemic inflammatory response. The serendipitous effect of CPHPC in depleting circulating SAP but leaving some SAP in amyloid deposits enabled the present use of anti-SAP antibodies to trigger unprecedented, clinically silent, elimination of visceral amyloid deposits by macrophages.
The same therapeutic approach should be effective in human amyloidosis, using human or humanised monoclonal antibodies or other antibody constructs. We therefore investigated two of our mouse monoclonal IgG2a anti-SAP antibodies, designated SAP-5 and Abp1, which bound to human SAP with similar affinities, on rates and off rates (Supplementary 10), which activated mouse complement in vitro producing C3 cleavage comparable to that produced by the sheep polyclonal anti-human SAP, and which had similar plasma half lives of ~4 days in wild type C57BL/6 mice. IgG2a antibodies were selected because mouse IgG1 activates mouse complement poorly if at all22. SAP-5 and Abp1 recognised different epitopes on human SAP (Supplementary 10) but were each as potent as the polyclonal sheep anti-SAP in eliminating amyloid in vivo (Supplementary 11 and 12).
Anti-SAP antibody could potentially elicit tissue damaging inflammation in amyloidotic tissues. However the present notable absence of any adverse effects presumably reflects the physiological nature of the macrophage reaction and is encouraging for clinical use of CPHPC and anti-SAP. Nevertheless, appropriate caution will be essential because systemic amyloidosis patients have widespread amyloid deposits in sensitive tissues, including the heart, blood vessel walls and nerves, which are not involved in the mouse AA model. Also, the trace amount of human SAP in normal glomerular basement membrane8 and elastic fibre microfibrils9 is a potential undesirable target for anti-SAP antibodies. It is therefore reassuring that there was no change in plasma biochemistry or any histological abnormality in human SAP transgenic mice treated with CPHPC followed by anti-human SAP antibodies (Supplementary 13).
Anti-Aβ antibodies are under intense investigation for treatment of Alzheimer’s disease and an in vivo imaging study23 has shown binding to some human systemic AL amyloid deposits by a monoclonal anti-light chain antibody which produces clearance of artefactual local human AL amyloidomas in mice24,25. However therapeutic anti-fibril antibodies will have to be reactive with each different type of amyloid whereas anti-SAP antibody treatment is applicable to all forms of amyloidosis and all human amyloid deposits. Since the SAP which is universal in amyloid is derived from the circulation, anti-SAP antibodies and complement proteins will also be able to reach the deposits, and macrophages are present in, or can access, all tissues. Management of systemic amyloidosis will always require maximum efforts to reduce amyloid fibril precursor protein production, if that is feasible, but the capacity to eliminate existing amyloid deposits would be a major therapeutic advance. A research and development collaboration between UCL and GlaxoSmithKline is now working towards clinical evaluation of this approach, and a candidate monoclonal anti-SAP antibody has been fully humanised for exploration of safety, efficacy and optimal clinical dosing.
METHODS SUMMARY
Induction of murine AA amyloidosis using amyloid enhancing factor and repeated casein injections, estimation of amyloid load in vivo and in vitro, and quantification of human SAP in serum and tissue extracts, were conducted as previously reported 6,4,10. Sheep and mouse anti-human SAP antibodies were raised by immunisation with isolated pure human SAP26 and mouse anti-human SAP hybridomas were cloned by standard methods.
Supplementary Material
Acknowledgements
The study was supported by MRC Programme Grant G97900510 to M.B.P. and P.N.H. and by the UCL Amyloidosis Research Fund. K.B. was supported by the Erik and Edith Fernströms Foundation for Medical Research and a Postdoctoral Fellowship from the Swedish Research Council. K.B. dedicates his work to his late father, Gunnar Bodin. We thank Siamon Gordon, Steve Wood, Simon Kolstoe, John Raynes, Paul Simons and Raya Al-Shawi for information, advice, reagents and support, and Beth Jones for processing the manuscript.
Footnotes
Supplementary Information is linked to the online version of the paper at www.nature.com/nature.
Full methods and associated references are provided in the Supplementary Information.
1. Pepys MB. Amyloidosis. Annu. Rev. Med. 2006;57:223–241. [PubMed]
2. Pepys MB, Dyck RF, de Beer FC, Skinner M, Cohen AS. Binding of serum amyloid P component (SAP) by amyloid fibrils. Clin. Exp. Immunol. 1979;38:284–293. [PubMed]
3. Pepys MB, et al. Amyloid P component. A critical review. Amyloid: Int. J. Exp. Clin. Invest. 1997;4:274–295.
4. Pepys MB, et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature. 2002;417:254–259. [PubMed]
5. Tennent GA, Lovat LB, Pepys MB. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer’s disease and systemic amyloidosis. Proc. Natl. Acad. Sci. USA. 1995;92:4299–4303. [PubMed]
6. Botto M, et al. Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nature Med. 1997;3:855–859. [PubMed]
7. Gillmore JD, et al. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br. J. Haematol. 2010;148:760–767. [PubMed]
8. Dyck RF, et al. Amyloid P-component is a constituent of normal human glomerular basement membrane. J. Exp. Med. 1980;152:1162–1174. [PMC free article] [PubMed]
9. Breathnach SM, et al. Amyloid P component is located on elastic fibre microfibrils of normal human tissues. Nature. 1981;293:652–654. [PubMed]
10. Hawkins PN, Myers MJ, Epenetos AA, Caspi D, Pepys MB. Specific localization and imaging of amyloid deposits in vivo using 123I-labeled serum amyloid P component. J. Exp. Med. 1988;167:903–913. [PMC free article] [PubMed]
11. Hawkins PN, Pepys MB. A primed state exists in vivo following histological regression of amyloidosis. Clin. Exp. Immunol. 1990;81:325–328. [PubMed]
12. Botto M, et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nature Genet. 1998;19:56–59. [PubMed]
13. Wessels MR, et al. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc. Natl. Acad. Sci. USA. 1995;92:11490–11494. [PubMed]
14. Van Rooijen N, Hendrikx E. In: Methods in Molecular Biology. Weissig V, editor. The Humana Press Inc; 2010. in press.
15. Zucker-Franklin D. Immunophagocytosis of human amyloid fibrils by leukocytes. J. Ultrastruct. Res. 1970;32:247–257. [PubMed]
16. Argilés À, García García M, Mourad G. Phagocytosis of dialysis-related amyloid deposits by macrophages. Nephrol. Dial. Transplant. 2002;17:1136–1138. [PubMed]
17. Nakamura Y, et al. A case of hereditary amyloidosis transthyretin variant Met 30 with amyloid cardiomyopathy, less polyneuropathy, and the presence of giant cells. Pathol. Int. 1999;49:898–902. [PubMed]
18. Verine J, et al. Clinical and histological characteristics of renal AA amyloidosis: a retrospective study of 68 cases with a special interest to amyloid-associated inflammatory response. Hum. Pathol. 2007;38:1798–1809. [PubMed]
19. Weiss SW, Page DL. Amyloid nephropathy of Ostertag with special reference to renal glomerular giant cells. Am. J. Pathol. 1973;72:447–455. [PubMed]
20. Lachmann HJ, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br. J. Haematol. 2003;122:78–84. [PubMed]
21. Lachmann HJ, et al. Natural history and outcome in systemic AA amyloidosis. N. Engl. J. Med. 2007;356:2361–2371. [PubMed]
22. Klaus GGB, Pepys MB, Kitajima K, Askonas BA. Activation of mouse complement by different classes of mouse antibody. Immunology. 1979;38:687–695. [PubMed]
23. Wall JS, Kennel SJ, Stuckey AC, Long MJ, Townsend DW, Smith GT, Wells KJ, Fu Y, Stabin MG, Weiss DT, Solomon A. Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. Blood. 2010 DOI 10.1182/blood-2010-03-273797. [PubMed]
24. Solomon A, Weiss DT, Wall JS. Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies. Cancer Biother. Radiopharm. 2003;18:853–860. [PubMed]
25. Solomon A, Weiss DT, Wall JS. Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11-1F4. Clin. Cancer Res. 2003;9:3831S–3838S. [PubMed]
26. de Beer FC, Pepys MB. Isolation of human C-reactive protein and serum amyloid P component. J. Immunol. Methods. 1982;50:17–31. [PubMed]